[HTML][HTML] The CD40-CD40L dyad as immunotherapeutic target in cardiovascular disease

LA Bosmans, L Bosch, PJH Kusters, E Lutgens… - Journal of …, 2021 - Springer
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.

LA Bosmans, L Bosch, PJH Kusters… - Journal of …, 2020 - europepmc.org
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

LA Bosmans, L Bosch… - Journal of …, 2021 - researchinformation.amsterdamumc …
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

LA Bosmans, L Bosch, PJH Kusters… - Journal of …, 2020 - epub.ub.uni-muenchen.de
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

LA Bosmans, L Bosch, PJH Kusters… - Journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

[HTML][HTML] The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

LA Bosmans, L Bosch, PJH Kusters… - Journal of …, 2021 - ncbi.nlm.nih.gov
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

LA Bosmans, L Bosch… - Journal of …, 2021 - mayoclinic.elsevierpure.com
Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment
of classical cardiovascular risk factors, a substantial portion of the population has elevated …